

1 **Prolonged viral shedding as a marker of severity in respiratory syncytial virus**
2 **bronchiolitis**

3
4 Raí André Silva Watanabe^a, PhD, Filipe Nishiyama^a, MD,
5 Larissa Lyra^b, MD, Bruno Sanchez Camargo^b, MD, Luciano
6 Kleber de Souza Luna^a, PhD, Danielle Dias Conte^a, MSc,
7 Ana Helena Perosa^a, PhD, Nancy Cristina Junqueira Bellei^a,
8 PhD.
9

10 **Affiliations:** ^aClinical Virology Laboratory, Infectious Diseases Unit, Medicine
11 Department, São Paulo Federal University, São Paulo, SP, Brazil; and ^b Hospital
12 São Paulo, São Paulo, SP, Brazil.

13
14 **Address correspondence to:** Raí André Silva Watanabe, Clinical Virology Laboratory,
15 Medicine Department, Hospital São Paulo, Rua Pedro de Toledo, 781, Vila Clementino,
16 15° andar frente, 04039-032, São Paulo, SP, Brazil, raiandre@yahoo.com, + 55 11 5576-
17 4848

18
19 **Institutional mailing addresses:**

20 Raí André Silva Watanabe: rai.watanabe@unifesp.br
21 Filipe Nishiyama: filipe.nishiyama@unifesp.br
22 Larissa Lyra: larissa.lyra@unifesp.br
23 Bruno Sanchez Camargo: bruno.sanchez@unifesp.br
24 Danielle Dias Conte: dd.conte@unifesp.br
25 Nancy Cristina Junqueira Bellei: nbellei@unifesp.br
26

27 **Email addresses:**

28 Raí André Silva Watanabe: raiandre@yahoo.com
29 Filipe Nishiyama: filipe.nishiyama@gmail.com
30 Larissa Lyra: larissalyra93@gmail.com
31 Bruno Sanchez Camargo: sanchez.bsc@gmail.com
32 Luciano Kleber de Souza Luna: lksluna@gmail.com
33 Danielle Dias Conte: daniellediasconte@gmail.com
34 Ana Helena Perosa: anaperosa@gmail.com
35 Nancy Cristina Junqueira Bellei: nbellei@uol.com.br
36

37 **Short title:** Viral shedding from RSV bronchiolitis
38

39 **Conflict of Interest Disclosures:** The authors have no conflicts of interest to
40 declare
41

42 **Abbreviations:**

43 **ICU** Intensive care unit
44 **IMV** Invasive mechanical ventilation
45 **RSV** Respiratory syncytial virus
46 **RT-qPCR** Reverse Transcription - quantitative Polymerase Chain Reaction

47 **SARS-CoV-2** Severe acute respiratory syndrome coronavirus 2

48

49 **Contributors Statement Page**

50 **Raí André Silva Watanabe:** data curation, formal analysis, investigation, project
51 administration, visualization, writing - original draft.

52 **Luciano de Souza Luna:** investigation, methodology, validation.

53 **Danielle Dias Conte, Ana Helena Perosa:** investigation.

54 **Larissa Lyra, Filipe Nishiyama, and Bruno Sanchez Camargo:** investigation, formal
55 analysis.

56 **Nancy Cristina Junqueira Bellei:** conceptualization, funding acquisition, supervision,
57 writing - review and editing.

58

59 **Ethics statement:** Ethics committee of UNIVERSIDADE FEDERAL DE SAO PAULO
60 gave ethical approval for this work under N. 3.009.916 - CEP/UNIFESP n. 1082/2018.
61 Consent was given from participants legal representatives to take part in the present study.

62 **Abstract**

63

64 **Background and Objectives**

65 Respiratory syncytial virus (RSV) is responsible for most cases of acute viral bronchiolitis
66 (AVB) in childhood. The association of factors such as RSV subtype, viral load, and viral
67 coinfection with severe disease is controversial. The objective is to describe the viral load
68 dynamics of RSV in children under 2 years with AVB, including the first viral load, peak
69 viral load, viral decay, and any possible association with severe disease.

70

71 **Methods**

72 73 inpatients with AVB and confirmed RSV infection were included. Viral load was
73 obtained through nasal swab samples daily during hospitalization and weekly after
74 discharge until absence of detection.

75

76 **Results**

77 44 of the patients were male, the mean age was 5.76 months, and comorbidities were found
78 in 15 (20.5%) of the patients. 54 (74%) of the patients had the peak viral load between the
79 4th and the 7th day of symptom onset. The mean duration of viral detection was 12.5 days.
80 There was no association between the first and peak viral load with markers of severe
81 disease. However, association was found between viral persistence exceeding 10 days and
82 the following factors: longer hospitalization period ($p=0.009$), length of ventilation support
83 ($p=0.044$), length of invasive mechanical ventilation ($p=0.035$), prolonged requirement of
84 nutritional support ($p=0.038$), and a longer course of antibiotic treatment ($p=0.024$). Age
85 was inversely correlated with most of the severity outcomes.

86

87 **Conclusion**

88 Despite the lack of association between RSV viral load values and disease severity,
89 prolonged viral shedding was associated with several adverse outcomes, which can
90 contribute to a better understanding of RSV disease, particularly as several interventions
91 are anticipated to become available in the coming years.

Prolonged viral shedding as a marker of severity in respiratory syncytial virus bronchiolitis

92
93
94
95

Introduction

96 Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections
97 and accounts for up to 80% of acute viral bronchiolitis (AVB) in childhood^{1,2,3}. Nearly
98 every child under two years of age is infected with the virus¹, and 2-3% require
99 hospitalization³. Recent data from the United States indicates that RSV is responsible for
100 9.3% of all hospitalizations among the pediatric population with an estimate burden of 1.2
101 billion dollars each year⁴. Two multi-site, international case-control studies about
102 pneumonia etiology in children under 5 years of age were conducted in the last decade and
103 RSV had the highest etiological fraction on the PERCH study and the second highest on the
104 GABRIEL study^{5,6}.

105 Up to 30% of AVB cases involve the detection of multiple viruses, and most cases occur
106 within the first six months of life^{3,7}. The risk factors for severe AVB includes lower age
107 (specially below 3 months), prematurity, bronchopulmonary dysplasia, congenital heart
108 disease, immunodeficiency, genetic disorders, neurological and neuromuscular disease,
109 tobacco exposure during pregnancy, lack of breastfeeding and male sex^{3,7}.

110 Studies on RSV shedding, and clinical severity vary in methodology, age groups studied,
111 diagnostic criteria, risk factors considered, and definitions of outcomes. Furthermore, there
112 are variations in the timing of viral load measurements and the methods used for
113 quantification⁸⁻¹³.

114 New interventions for managing RSV infections, such as vaccines and monoclonal
115 antibodies, have recently been approved¹⁴. To assess their impact on the dynamics of RSV-
116 associated AVB, it is essential to increase the understanding of RSV viral load.

117 The study's objective was to characterize the dynamics of RSV viral load from the time of
118 hospital admission to the point of viral shedding, encompassing both inpatients and
119 outpatients. Additionally, the study intended to investigate potential associations between
120 viral load, the RSV subgroup type, the detection of multiple viruses, and patient
121 characteristics (such as age, gender, and comorbidities) and their impact on the severity of
122 clinical outcomes.

123

124 **Materials and Methods**

125 *Study Design:* The study aimed to characterize the dynamics of RSV viral load, tracking it
126 from hospital admission to the point of final viral shedding, in both inpatients and
127 outpatients. In addition, the study sought to investigate potential associations between viral
128 load, the RSV subgroup type, the presence of multiple viruses excluding severe acute
129 respiratory syndrome coronavirus 2 (SARS-CoV-2), and patient characteristics (such as
130 age, gender, and comorbidities) in relation to the severity of clinical outcomes.

131 The inclusion criteria for the study were as follows:

- 132 1. Hospitalized patients under 2 years of age diagnosed with acute viral bronchiolitis
133 and not expected to be discharged within the next 24 hours.
- 134 2. Initial assessment confirming RSV infection through reverse transcription –
135 quantitative Polymerase Chain Reaction (RT-qPCR).

136 The exclusion criteria were:

- 137 1. Loss of follow-up before a viral load sample with no RSV detection.
- 138 2. Patients with less than 3 collected samples.
- 139 3. Detection of SARS-CoV-2 through RT-qPCR for a child included in the pandemic
140 period.

141

142 *Data collection:* The study utilized a convenience sample of children admitted to the
143 hospital's pediatric service with a clinical diagnosis of AVB. These children underwent
144 nasopharyngeal swabs to detect RSV through RT-qPCR. The diagnosis of AVB was made
145 by the attending pediatric physician in accordance with the guidelines of the American
146 Academy of Pediatrics¹⁵. Nasopharyngeal swab samples were obtained by the team
147 coordinator, trained resident physicians, or the on-duty physiotherapist for laboratory
148 confirmation of RSV infection. Samples were collected daily during the period of the
149 infant's hospitalization and weekly after hospital discharge, with the collection stopping
150 when no further RSV was detected in two consecutive samples. The day of symptom onset
151 was defined as the first respiratory or systemic symptom of RSV infection: fever, cough,
152 runny nose, nasal obstruction, cyanosis, apnea, respiratory distress or wheezing.

153

154 *Laboratory Methods:* Each collected swab was preserved in 2.0 mL of sterile lactated
155 Ringer's solution and immediately transported to the virology laboratory for RSV
156 molecular screening on the same day or stored at -80°C until investigation. The RNA of
157 swab samples was purified using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden,
158 Germany) according to the manufacturer's instructions. Molecular detection of RSV was
159 performed by a duplex quantitative RT-qPCR with TaqMan Fast Virus 1-Step Master Mix
160 reagents (Applied Biosystems, Vilnius, Lithuania). The 20 µL of reaction volume
161 contained 1 µM of each primer and 250 nM of the probe for RSV detection (labeled with
162 FAM dye), aimed at the Matrix gene¹⁶, and 250 nM of each primer and probe (labeled with
163 VIC dye) for human ribonuclease P gene detection as an internal control¹⁷. Thermocycling
164 conditions were performed on a 7500 Real-Time PCR System (Applied Biosystems), as

165 follow: 50°C for 2 min., 95°C for 20 sec., followed by 45 cycles of 95°C for 15 sec., and
166 55°C for 30 sec. (data collection). The cycle threshold of 35 was adopted as a cut-off for
167 the human ribonuclease P and 38 for the RSV RT-qPCR.

168

169 *Viral load analysis:* The viral load was measured from a standard curve generated as
170 described elsewhere¹⁸, with an efficiency of 100.52%. The viral load was expressed in
171 Log₁₀ RNA copies/mL.

172

173 *RSV Subtype:* The protocol of RSV subtyping was performed by Fiocruz laboratory with
174 the sample of the highest viral load of each patient¹⁹.

175

176 *Influenza and Rhinovirus detection:* An in-house real-time PCR was performed to detect
177 Influenza A, B and rhinovirus with AgPath-ID™ One-Step RT-PCR Reagents
178 (ThermoFischer) according to the manufacturer's instructions. The primers and probes used
179 for each virus detection have been published elsewhere^{20,21}. A positive result was
180 considered with a Ct < 40.

181

182 *Statistics:* Sample size calculation was performed using G Power 3.1.9.7, based on an effect
183 size of 0.4, power of 80%, alfa error probability of 5% using a linear regression model with
184 7 predictor variables. The number of patients to achieve statistical significance was 44.
185 Data was stored in Microsoft excel 365 sheets. Statistical analysis was obtained using
186 Jamovi (version 2.3.13) with alfa error probability of 5% and confidence interval of 95%.
187 Graphs were built with Microsoft excel 365 and SPSS 26th edition.

188 Continuous variables were described as mean with standard deviation and median with
189 interquartile range, and categorical variables as frequency rates. The 10-day cutoff for viral
190 persistence as a categorical variable was based on the median number obtained as viral

191 persistence.

192 Results were considered statistically significant when p value was below 0,05. Multiple
193 linear regression was used accordingly. R^2 was used to report the adequation of the model
194 to the data and for effect size. Two models were performed, according to the equation:

$$195 \quad y = \beta_0 + \beta_1 \cdot x + \varepsilon$$

196 y = dependent variable

197 x = covariates

198 β_0 = intercept

199 β_1 = angular coefficient

200 ε = error

201

202 Model A: Dependent variables: (1) viral persistence; (2) peak viral load; (3) first viral load.

203 Covariates: (1) age; (2) sex; (3) RSV subtype; (4) comorbidities; (5) rhinovirus.

204 Model B: Dependent variables (days of each outcome): (1) hospitalization; (2) fever; (3)
205 use of oxygen; (4) ICU; (5) any ventilation support; (6) IMV; (7) additional nutrition
206 support; (8) use of antibiotics. Covariates: (1) age; (2) peak viral load; (3) viral persistence
207 over 10 days; (4) sex; (5) RSV subtype; (6) comorbidities; (7) rhinovirus.

208

209 **Results**

210 Out of a total of 191 hospitalized patients under 2 years with AVB who were tested for
211 RSV infection, 112 (63,9%) were positive for RSV and 73 patients were enrolled in the
212 study. The main reasons of the exclusion for the 48 patients that had RSV detection were:
213 (1) discharge under 24 hours; (2) hospital transfer before 3 samples collected; (3) refusal to
214 participate. One patient had SARS-CoV-2 detection. In 2019, 40 patients were included,
215 and in 2021, 33 patients were included. A total of 548 nasopharyngeal samples were

216 collected from the enrolled patients, averaging 7.5 samples per patient. Out of these, 496
217 (90.5%) were obtained during the hospitalization period and were collected daily. Before
218 discharge, 42 patients (57.5%) exhibited complete viral clearance.

219

220 *Characteristics of study population:* The characteristics of the study population are outlined
221 in Table 1. Comorbidities were observed in 9 patients with prematurity (12.3%), 3 patients
222 with cardiac and neurological diseases (4.1% each), and one patient with one of the
223 following: immunodeficiency, bronchopulmonary dysplasia, hematologic disease, renal
224 disease, and genetic syndrome. Two of the patients had more than one comorbidity. None
225 of the premature infants had a gestational age below 30 weeks (ranging from 30 to 36
226 weeks), and only one received palivizumab. The patient who received palivizumab had
227 down syndrome, bronchopulmonary dysplasia, and cardiac disease (patient number 38
228 from figure 2).

229 Recurrent wheezing was not considered a comorbidity, and 8 patients in the 2019 cohort
230 had experienced at least one previous wheezing episode. Among the 12 cases with
231 rhinovirus co-infection, lower viral loads and shorter persistence of rhinovirus was
232 observed compared to RSV values of the same patient. The Ct values for rhinovirus RNA
233 detection ranged from 28 to 39.

234

235 *Viral Load Analysis:* All patients had their first nasopharyngeal swab samples collected on
236 the first or second day of hospitalization. Upon admission, the mean day of symptom onset
237 was 5.11 ± 2.54 , with a median of 5 (ranging from 4 to 6). Three caregivers reported
238 symptoms lasting for more than 12 days at the time of admission.

239 The initial viral load in the first sample ranged from 4 to 8.01 log₁₀ copies/ml, with a mean

240 of 6.03 ± 1.10 and a median of 6.34 (ranging from 5.12 to 6.79). Peak viral load varied
241 between 4.14 and 8.01 log₁₀ copies/ml, with a mean of 6.3 ± 0.98 and a median of 6.49
242 (ranging from 5.67 to 6.92). In 40 patients (54.8%), the first viral load was identical to the
243 peak viral load. The time to reach the peak viral load after the onset of symptoms is
244 detailed in Table 2.

245 Individual viral load decay can be observed in Figures 1 to 4, while the distribution of viral
246 loads for all patients based on the onset of symptoms is illustrated in Figure 5.

247 The duration of viral shedding (viral persistence) was determined as the last day of RSV
248 detection in relation to symptom onset. The mean viral persistence was 12.5 ± 5.72 days,
249 with a median of 10 days (ranging from 9 to 15 days) and varying from 6 to 33 days. A
250 total of 33 patients (45.2%) exhibited viral persistence exceeding the median of 10 days. To
251 provide a more detailed perspective, viral persistence was further analyzed on a weekly
252 basis, considering that samples were collected every 7 days, as displayed in Table 3.

253 No statistically significant associations were found between viral load markers (first viral
254 load, peak viral load, and viral persistence) and the various covariates, including age,
255 gender, RSV subgroup, comorbidities, rhinovirus co-detection, and recurrent wheezing.
256 The complete linear regression analysis for the model A is shown on table 4.

257

258 *Analysis of severity outcomes:* Frequency and length of studied outcomes are described on
259 table 5. Severity outcomes were studied as dependent variables of the multiple linear
260 regression. Possible variables of association were analyzed as covariates. Age was
261 inversely correlated with higher hospitalization period ($p=0.039$), more days of oxygen use
262 ($p=0.039$) and need for ICU ($p=0.045$). Patients who experienced viral persistence for more
263 than 10 days were found to have a significant correlation with a longer hospitalization

264 period ($p=0.009$), increased days of ventilation support ($p=0.044$), extended duration of
265 IMV ($p=0.035$), prolonged requirement for nutritional support ($p=0.038$), and a longer
266 course of antibiotic treatment ($p=0.024$). Mean and standard deviation of studied outcomes
267 and p value for patients according to the 10-day RSV shedding are show on table 6. The
268 complete linear regression analysis for model B is shown on table 7.

269

270 **Discussion**

271 Our study presents the most extensive longitudinal examination of RSV viral load in AVB
272 patients, with an analysis based on severity outcomes. Despite utilizing a convenience
273 sample over a two-year period, we successfully detected RSV in 64% of AVB patients that
274 were submitted to viral detection. The study spanned two years, with a gap between them
275 due to the outbreak of the SARS-CoV-2 pandemic, which prompted isolation measures and
276 the closure of schools. This was justified by the fact that several other studies reported a
277 delayed RSV outbreak in the first year of SARS-CoV-2 pandemic²²⁻²⁴. A previous study
278 from our group described the patients from the pre-pandemic period²⁵. Nevertheless, our
279 findings align with the rates reported in existing literature^{3,7}. It's worth noting that the
280 pandemic's impact was evident in the second year of the study, with the absence of children
281 experiencing recurrent wheezing.

282 Upon hospital admission, the reported time since symptom onset averaged 5 days, aligning
283 with the point in the disease course described in the literature when symptoms typically
284 worsen⁷.

285 Our study revealed several findings that were consistent with existing literature. These
286 included a majority of male patients, a higher incidence of the disease among younger
287 patients (particularly those under 6 months of age), and a predominance of RSV subgroup

288 A^{7,26-29}. Notably, the proportion of severe outcomes in our study, such as the need for ICU
289 admission (46.6%) and IMV (24.7%), was significantly higher than previously reported.
290 This could be attributed to the exclusion of patients who were discharged from the hospital
291 early and the specific characteristics of our hospital^{7,30}.

292
293 *Viral load dynamics:* Viral load and viral persistence have been the subject of investigation
294 in several studies aiming to comprehend RSV viral decay. For instance, Takeyama et al.
295 and Hall et al. collected daily RSV samples during hospitalization but did not continue to
296 monitor patients after discharge^{9,31}. Takeyama et al. reported similar findings, including the
297 time to reach peak viral load and the absence of an association between viral load and RSV
298 subgroup with disease severity.

299 In the study conducted by Brint et al.³², RSV samples were collected daily throughout the
300 hospitalization period and for specific days following discharge, extending up to the 28th
301 day, even when RSV was no longer detectable. In that study, 11.8% of patients exhibited
302 RSV detection for over 1 month, which was a higher rate compared to our findings. The
303 discrepancy in results, including a higher rate of viral load rebound (19.6%) compared to
304 our study (12.3%), could potentially be attributed to variations in viral load measurement
305 techniques and the systematic collection of samples even after RSV was no longer
306 detectable. Viral load rebound was defined as a 10-fold increase in the viral load after a
307 nadir, which happened after the 8th day of symptom onset, in two consecutive viral loads.

308 Viral load and viral persistence were not found to be associated with any of the patient
309 characteristics (age, sex, comorbidities), RSV subgroup, or the presence of rhinovirus. This
310 aligns with findings from other studies^{9,32,33}.

311

312 *Severity Outcomes:* Age was inversely associated with most severity outcomes, as widely
313 reported^{3,28}. Our study could not find any association between quantitative viral load and
314 severity outcomes. This association is controversial in the literature, with studies showing a
315 positive association^{8,11}, inverse association^{12,33} and others bringing no association at all^{34,35}.
316 Also, RSV subtype was not associated with severity outcomes; some studies corroborate
317 this finding^{36,37}, while others associate disease severity with the subgroup A^{38,39}.
318 The primary and original data in our study was the association between viral persistence
319 exceeding 10 days and most severity outcomes. The viral persistence may be a red flag for
320 worsening outcomes and could encourage RSV detection and viral load quantification in
321 patients with prolonged need for hospitalization and critical care. Future studies regarding
322 treatment with antivirals and monoclonal antibodies could also address the benefit in RSV
323 AVB patients with prolonged viral shedding.
324
325 Several limitations were experienced in our study. The accuracy of caregiver-provided
326 information regarding the onset of symptoms, essential for standardizing the viral load
327 curve, may be influenced by various factors, particularly prior upper airway infections,
328 especially given the seasonal nature of respiratory viruses. There was an important loss of
329 patients due to hospital transfer, as our hospital ward was not sufficient to hold all the
330 patients during the peak of respiratory viruses' seasonality. We also expected more patients
331 with comorbidities, and for that reason we could not analyze them separately. Additionally,
332 we did not explore the co-detection of other viruses and RSV genotypes, apart from the
333 subgroup. It's important to note that the severity of AVB can be influenced by a multitude
334 of factors related to the virus, the patient, and external variables. Investigating all these
335 factors simultaneously is a challenging in study design.

336

337 **Conclusion**

338 Predictors of bronchiolitis severity can be highly complex. In addition to younger age, our
339 study suggests that RSV viral persistence is associated to more severe disease. Further
340 research into the dynamics of viral load in new studies may validate these findings. The
341 information we have provided on viral shedding can contribute to a better understanding of
342 RSV disease, particularly as several interventions, including vaccines, antivirals, and
343 monoclonal antibodies, are anticipated to become available in the coming years.

References

1. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. *Am J Dis Child*. 1986 Jun;140(6):543-6. doi: 10.1001/archpedi.1986.02140200053026. PMID: 3706232.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet*. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. PMID: 20399493; PMCID: PMC2864404.
3. Meissner HC. Viral Bronchiolitis in Children. *N Engl J Med*. 2016 Jan 7;374(1):62-72. doi: 10.1056/NEJMra1413456.
4. Simões EAF. The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis. *J Infect Dis*. 2022 Aug 15;226(Suppl 2):S143-S147. doi: 10.1093/infdis/jiac211.
5. Bénet T, Sánchez Picot V, Messaoudi M, et al. Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network; Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network. Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. *Clin Infect Dis*. 2017 Aug 15;65(4):604-612. doi: 10.1093/cid/cix378.
6. Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. *Lancet*. 2019 Aug 31;394(10200):757-779. doi: 10.1016/S0140-6736(19)30721-4. Epub 2019 Jun 27. Erratum in: *Lancet*. 2019 Aug 31;394(10200):736.
7. Kyler KE, McCulloh RJ. Current Concepts in the Evaluation and Management of Bronchiolitis. *Infect Dis Clin North Am*. 2018 Mar;32(1):35-45. doi: 10.1016/j.idc.2017.10.002. Epub 2017 Dec 18.
8. El Saleeby CM, Bush AJ, Harrison LM, et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. *J Infect Dis*. 2011 Oct 1;204(7):996-1002. doi: 10.1093/infdis/jir494.
9. Takeyama A, Hashimoto K, Sato M, et al. Respiratory syncytial virus shedding by children hospitalized with lower respiratory tract infection. *J Med Virol*. 2016 Jun;88(6):938-46. doi: 10.1002/jmv.24434. Epub 2015 Dec 1.
10. Hijano DR, Brazelton de Cardenas J, Maron G, et al. Clinical correlation of influenza and respiratory syncytial virus load measured by digital PCR. *PLoS One*. 2019 Sep 3;14(9):e0220908. doi: 10.1371/journal.pone.0220908.
11. Haddadin Z, Beveridge S, Fernandez K, et al. Respiratory Syncytial Virus Disease Severity in Young Children. *Clin Infect Dis*. 2021 Dec 6;73(11):e4384-e4391. doi: 10.1093/cid/ciaa1612.
12. Brenes-Chacon H, Garcia-Mauriño C, Moore-Clingenpeel M, et al. Age-dependent Interactions Among Clinical Characteristics, Viral Loads and Disease Severity in Young Children With Respiratory Syncytial Virus Infection. *Pediatr Infect Dis J*. 2021 Feb 1;40(2):116-122. doi: 10.1097/INF.0000000000002914.

13. Hartmann K, Liese JG, Kemmling D, et al. Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤ 5 Years (INSPIRE Study). *J Infect Dis*. 2022 Aug 26;226(3):386-395. doi: 10.1093/infdis/jiac137.
14. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. *Lancet Infect Dis*. 2023 Jan;23(1):e2-e21. doi: 10.1016/S1473-3099(22)00291-2. Epub 2022 Aug 8.
15. Ralston SL, Lieberthal AS, Meissner HC, et al. American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. 2014 Nov;134(5):e1474-502. doi: 10.1542/peds.2014-2742. Erratum in: *Pediatrics*. 2015 Oct;136(4):782.
16. Fry AM, Chittaganpitch M, Baggett HC, et al. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand. *PLoS One*. 2010 Nov 30;5(11):e15098. doi: 10.1371/journal.pone.0015098.
17. Emery SL, Erdman DD, Bowen MD, et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. *Emerg Infect Dis*. 2004 Feb;10(2):311-6. doi: 10.3201/eid1002.030759.
18. Cruz JS, de Souza Luna LK, Alves VRG, et al. Viral load of respiratory syncytial virus among children from primary care and hospital settings admitted to a university hospital in Brazil (2009-2013). *J Med Virol*. 2021 Jun;93(6):3397-3400. doi: 10.1002/jmv.26185. Epub 2020 Sep 30.
19. Fröhlich GC, Gregianini TS, Pinheiro FG, et al. LACEN-RS Team. Resurgence of human respiratory syncytial virus during COVID-19 pandemic in Southern Brazil. *J Med Virol*. 2024 Mar;96(3):e29551. doi: 10.1002/jmv.29551. PMID: 38506236.
20. Shu B, Kirby MK, Davis WG, et al. Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. 2021;27(7):1821-1830. doi: 10.3201/eid2707.210462. PMID: 34152951; PMCID: PMC8237866.
21. Gagliardi TB, Goldstein ME, Song D, et al. Rhinovirus C replication is associated with the endoplasmic reticulum and triggers cytopathic effects in an in vitro model of human airway epithelium. *PLoS Pathog*. 2022 Jan 7;18(1):e1010159. doi: 10.1371/journal.ppat.1010159. PMID: 34995322; PMCID: PMC8741012.
22. Varela FH, Scotta MC, Polese-Bonatto M, et al. COVIDa study group. Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community. *J Glob Health*. 2021 Mar 1;11:05007. doi: 10.7189/jogh.11.05007.
23. Eden, JS., Sikazwe, C., Xie, R. et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. *Nat Commun* 13, 2884 (2022). <https://doi.org/10.1038/s41467-022-30485-3>
24. Garg I, Shekhar R, Sheikh AB, et al. Impact of COVID-19 on the Changing Patterns of Respiratory Syncytial Virus Infections. *Infect Dis Rep*. 2022 Jul 24;14(4):558-568. doi: 10.3390/idr14040059.
25. Watanabe RAS, Cruz JS, de Souza Luna LK, et al. Respiratory syncytial virus: viral load, viral decay, and disease progression in children with bronchiolitis. *Braz J Microbiol*. 2022 Sep;53(3):1241-1247. doi: 10.1007/s42770-022-00742-0. Epub 2022 Apr 1.

26. Calvo C, Pozo F, García-García ML, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. *Acta Paediatr.* 2010 Jun;99(6):883-7. doi: 10.1111/j.1651-2227.2010.01714.x. Epub 2010 Feb 16.
27. Mansbach JM, Piedra PA, Teach SJ, et al. MARC-30 Investigators. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. *Arch Pediatr Adolesc Med.* 2012 Aug;166(8):700-6. doi: 10.1001/archpediatrics.2011.1669.
28. Espinosa Y, San Martín C, Torres AA, et al. Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants. *Int J Mol Sci.* 2017 Mar 21;18(3):654. doi: 10.3390/ijms18030654.
29. Rodriguez-Fernandez R, Tapia LI, Yang CF, et al. Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis. *J Infect Dis.* 2017 Dec 27;217(1):24-34. doi: 10.1093/infdis/jix543.
30. Ghazaly M, Nadel S. Characteristics of children admitted to intensive care with acute bronchiolitis. *Eur J Pediatr.* 2018 Jun;177(6):913-920. doi: 10.1007/s00431-018-3138-6. Epub 2018 Apr 13.
31. Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. *J Pediatr.* 1976 Jul;89(1):11-5. doi: 10.1016/s0022-3476(76)80918-3.
32. Brint ME, Hughes JM, Shah A, et al. Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants. *Pediatr Res.* 2017 Nov;82(5):872-880. doi: 10.1038/pr.2017.173. Epub 2017 Aug 9.
33. Thwaites RS, Coates M, Ito K, et al. Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. *Am J Respir Crit Care Med.* 2018 Oct 15;198(8):1074-1084. doi: 10.1164/rccm.201712-2567OC.
34. Walsh EE, Wang L, Falsey AR, et al. Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection. *J Infect Dis.* 2018 Jun 20;218(2):208-217. doi: 10.1093/infdis/jiy106.
35. Souza AP, Leitão LA, Luisi F, et al. Lack of association between viral load and severity of acute bronchiolitis in infants. *J Bras Pneumol.* 2016 Jul-Aug;42(4):261-265. doi: 10.1590/S1806-37562015000000241.
36. Devincenzo, J. Natural Infection of Infants with Respiratory Syncytial Virus Subgroups A and B: A Study of Frequency, Disease Severity, and Viral Load. *Pediatr Res* 56, 914–917 (2004). <https://doi.org/10.1203/01.PDR.0000145255.86117.6A>
37. Espinosa Y, San Martín C, Torres AA, et al. Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants. *Int J Mol Sci.* 2017 Mar 21;18(3):654. doi: 10.3390/ijms18030654.
38. Jafri HS, Wu X, Makari D, Henrickson KJ. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department

with lower respiratory tract infection or apnea. *Pediatr Infect Dis J.* 2013 Apr;32(4):335-40. doi: 10.1097/INF.0b013e318282603a.

39. Tabarani CM, Bonville CA, Suryadevara M, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. *Pediatr Infect Dis J.* 2013 Dec;32(12):e437-42. doi: 10.1097/INF.0b013e3182a14407.









Figure 1. RSV viral load decay, patients 1 to 21. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization.



















Figure 2. RSV viral load decay, patients 22 to 39. Horizontal line correspond to the cut of viral detection. Vertical lines indicate period of hospitalization.







Figure 3. RSV viral load decay, patients 40 to 55. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization. Yellow strips correspond to intensive care unit period.

Figure 4. RSV viral load decay, patients 56 to 73. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization. Yellow strip correspond to intensive care unit period and red strip to invasive mechanical ventilation period.







Figure 5. RSV viral load of samples from all patients according to symptom onset.



Patient 22**Patient 23****Patient 24****Patient 25****Patient 26****Patient 27****Patient 28****Patient 29****Patient 30****Patient 31****Patient 32****Patient 33****Patient 34****Patient 35****Patient 36****Patient 37****Patient 38****Patient 39**



medRxiv preprint doi: <https://doi.org/10.1101/2024.08.29.24312713>; this version posted August 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



RSV Viral Load (Log10 copies/ml)

10
8
6
4
2
0

0 5 10 15 20 25 30

Days after beginning of symptoms

Preprint doi: <https://doi.org/10.1101/2024.08.29.24312713>; this version posted August 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

